Intercept Pharmaceuticals (DB:I4P) - Prezzo delle azioni, notizie e analisi

I4P Panoramica delle azioni

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Maggiori dettagli

I4P analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 56.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 42.37% all'anno

Gli utili sono cresciuti del 22.4% all'anno negli ultimi 5 anni

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Intercept Pharmaceuticals, Inc. Concorrenti

Formycon

XTRA:FYB

€827.2m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Intercept Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$17.52
Massimo di 52 settimane	US$19.97
Minimo di 52 settimane	US$8.16
Beta	0.88
1Variazione di 1 mese	0.46%
Variazione a 3 mesi	90.52%
Variazione di 1 anno	14.92%
3Variazione a 3 anni	-45.23%
Variazione a 5 anni	-79.17%
Variazione dall'IPO	17.29%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	I4P	DE Biotechs	DE Mercato
7D	-0.8%	-0.7%	-0.02%
1Y	14.9%	-17.2%	8.2%

Ritorno vs Industria: I4P ha superato il German Biotechs che ha restituito -17.2 % nell'ultimo anno.

Rendimento vs Mercato: I4P ha superato il mercato German che ha restituito 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is I4P's price volatile compared to industry and market?
I4P volatility
I4P Average Weekly Movement	22.8%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Prezzo delle azioni stabile: Il prezzo delle azioni di I4P è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di I4P è aumentata da 15% a 23% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Intercept Pharmaceuticals con la sua capitalizzazione di mercato?
I4P statistiche fondamentali
Capitalizzazione di mercato	€742.08m
Guadagni(TTM)	-€53.66m
Ricavi(TTM)	€296.65m

2.5x

Rapporto P/S

-13.8x

Rapporto P/E

I4P è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
I4P Conto economico (TTM)
Ricavi	US$317.68m
Costo del fatturato	US$632.00k
Profitto lordo	US$317.05m
Altre spese	US$374.52m
Guadagni	-US$57.47m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.37
Margine lordo	99.80%
Margine di profitto netto	-18.09%
Rapporto debito/patrimonio netto	311.6%

Come si è comportato I4P nel lungo periodo?

Vedi performance storica e confronto

I4P Panoramica delle azioni

Premi

Analisi del rischio

Intercept Pharmaceuticals, Inc. Concorrenti

XTRA:FYB

€827.2m

XTRA:BIO3

€1.4b

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast to breakeven in 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast to breakeven in 2024

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021)

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc

Forecast to breakeven in 2024

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020)

Intercept Pharmaceuticals, Inc. announced a financing transaction

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020)

Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Independent Director Daniel Welch has left the company

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020)

CFO, Treasurer & Principal Accounting Officer has left the company